The anti-inflammatory potential of an oral p38 MAPK inhibitor in humans in vivo suggests that p38 MAPK inhibitors may provide a new therapeutic option in the treatment of inflammatory diseases. Boehringer Ingelheim. 2002 Branger J, et al
J. Pitcher, M. Lohse, J. Codina, M. Caron, and R. Lefkowitz. Biochemistry, 31 (12):
3193-7(March 1992)Pitcher, J Lohse, M J Codina, J Caron, M G Lefkowitz, R J HL16037/HL/NHLBI
NIH HHS/United States Research Support, U.S. Gov't, P.H.S. United
states Biochemistry Biochemistry. 1992 Mar 31;31(12):3193-7..
M. Lohse, R. Lefkowitz, M. Caron, and J. Benovic. Proc Natl Acad Sci U S A, 86 (9):
3011-5(May 1989)Lohse, M J Lefkowitz, R J Caron, M G Benovic, J L Comparative Study
Research Support, Non-U.S. Gov't United states Proceedings of the
National Academy of Sciences of the United States of America Proc
Natl Acad Sci U S A. 1989 May;86(9):3011-5..
S. Graham, P. Combes, M. Crumiere, K. Klotz, and J. Dickenson. Eur J Pharmacol, 420 (1):
19-26(May 2001)Graham, S Combes, P Crumiere, M Klotz, K N Dickenson, J M Research
Support, Non-U.S. Gov't Netherlands European journal of pharmacology
Eur J Pharmacol. 2001 May 18;420(1):19-26..